222 related articles for article (PubMed ID: 23393220)
1. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
2. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
3. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
4. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.
Shen HW; Jiang XL; Yu AM
Drug Metab Dispos; 2011 Jul; 39(7):1227-34. PubMed ID: 21464174
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
8. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
[TBL] [Abstract][Full Text] [Related]
9. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
10. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.
Jiang XL; Shen HW; Mager DE; Schmidt S; Yu AM
Acta Pharm Sin B; 2016 Sep; 6(5):492-503. PubMed ID: 27709018
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
Wu C; Jiang XL; Shen HW; Yu AM
Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
[TBL] [Abstract][Full Text] [Related]
12. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Halberstadt AL; Nichols DE; Geyer MA
Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
[TBL] [Abstract][Full Text] [Related]
13. Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.
Shen HW; Jiang XL; Yu AM
Bioanalysis; 2009 Apr; 1(1):87-95. PubMed ID: 20523750
[TBL] [Abstract][Full Text] [Related]
14. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
15.
Eckernäs E; Macan-Schönleben A; Andresen-Bergström M; Birgersson S; Hoffmann KJ; Ashton M
Xenobiotica; 2023 Dec; 53(8-9):515-522. PubMed ID: 37916667
[No Abstract] [Full Text] [Related]
16. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
[TBL] [Abstract][Full Text] [Related]
17. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Ott J
J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
[TBL] [Abstract][Full Text] [Related]
18. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of N,N-dimethyltryptamine in Humans.
Good M; Joel Z; Benway T; Routledge C; Timmermann C; Erritzoe D; Weaver R; Allen G; Hughes C; Topping H; Bowman A; James E
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):311-327. PubMed ID: 37086340
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]